SCHEMBL607849

SCHEMBL607849

OC(CN1CCN(Cc2cccnc2)CC1)Cn1c2ccccc2c2cc(Br)ccc21

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.66
KMT2A Q03164 3/20 0.66
RAD52 P43351 2/20 0.66
LMNA P02545 4/20 0.62
GAA P10253 1/20 0.62
BAX Q07812 1/20 0.54
MAPT P10636 6/20 0.53
MAPK1 P28482 4/20 0.53
TP53 P04637 2/20 0.53
CYP3A4 P08684 1/20 0.53
ALOX15 P16050 1/20 0.53
HTT P42858 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.51
POLB P06746 2/20 0.49
ALDH1A1 P00352 1/20 0.49
HPGD P15428 1/20 0.49
HSD17B10 Q99714 1/20 0.49
CNR2 P34972 1/20 0.48
ATM Q13315 1/20 0.47
DNM1 Q05193 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL609727 0.96 BAX (0.58) MEN1KMT2ARAD52LMNAGAA
SCHEMBL607057 0.89 MEN1 (0.69) MEN1KMT2ARAD52LMNAGAA
SCHEMBL607023 0.85 LMNA (0.73) MEN1KMT2ARAD52LMNAGAA
SCHEMBL6815606 0.85 MEN1 (0.88) MEN1KMT2ARAD52LMNAGAA
SCHEMBL607402 0.83 RAD52 (0.69) MEN1KMT2ARAD52LMNAGAA
SCHEMBL607210 0.83 MEN1 (0.69) MEN1KMT2ARAD52LMNAGAA
SCHEMBL608163 0.82 MEN1 (0.68) MEN1KMT2ARAD52LMNAGAA
SCHEMBL609372 0.81 MEN1 (0.67) MEN1KMT2ARAD52LMNAGAA
SCHEMBL607481 0.81 MEN1 (0.67) MEN1KMT2ARAD52LMNAGAA
SCHEMBL607287 0.81 MEN1 (0.72) MEN1KMT2ARAD52LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP claimed
EP-1237887-A1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2002-09-11 EP claimed
WO-2001029028-A1 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-04-26 WO claimed
US-8410110-B2 9-(piperazinylalkyl) carbazoles as Bax-modulators MERCK SERONO SA (CH) 2013-04-02 US disclosed
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2012-02-16 US disclosed
US-8053436-B1 9-(piperazinylalkyl) carbazoles as bax-modulators MERCK SERONO SA (CH) 2011-11-08 US disclosed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP disclosed
EP-1237887-A1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2002-09-11 EP disclosed
WO-2001029028-A1 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS BCL2, BAX, BAD MEN1 3810/4885KMT2A 732/4885RAD52 3656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.